Cenicriviroc 150 mg ( DrugBank: Cenicriviroc )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 1 |
94. Primary sclerosing cholangitis
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02653625 (ClinicalTrials.gov) | March 14, 2016 | 8/1/2016 | PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis | PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | Drug: Cenicriviroc 150 mg | Tobira Therapeutics, Inc. | NULL | Completed | 18 Years | 75 Years | All | 24 | Phase 2 | United States;Canada |